Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

5/22/24 7:11:41 AM ET

$RGLS

$TECH

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGLS alert in real time by email

Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Get the next $RGLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RGLS
$TECH

Company	Date	Price Target	Rating	Analyst
Regulus Therapeutics Inc. $RGLS	8/2/2024	$7.00	Outperform	Oppenheimer
Bio-Techne Corp $TECH	5/22/2024	$85.00	Buy → Neutral	Citigroup
Regulus Therapeutics Inc. $RGLS	3/18/2024	$6.00	Outperform	Leerink Partners
Bio-Techne Corp $TECH	2/8/2024	$80.00	Sector Outperform	Scotiabank
Bio-Techne Corp $TECH	2/2/2024	$65.00	Buy → Hold	Stifel
Bio-Techne Corp $TECH	12/7/2023	$80.00	Buy	UBS
Bio-Techne Corp $TECH	8/28/2023		Outperform	William Blair
Bio-Techne Corp $TECH	1/10/2023	$90.00	Underweight → Equal Weight	Wells Fargo

More analyst ratings

$RGLS
$TECH
Financials

Live finance-specific insights

Bio-Techne Releases Second Quarter Fiscal 2025 Results
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million.GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago.Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy workflow solutions, led to 8% organic growth in our Protein Sciences Segment (7% reported).Strong commercial execution in Diagnostics & Spatial Biology led to 12% organic growth (12% report
2/5/25 6:30:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Bio-Techne Declares Dividend
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s
2/5/25 6:30:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference call at 8:30 a.m. ET today SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovati
1/29/25 7:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care

$RGLS
$TECH
Press Releases

Fastest customizable press release news feed in the world

Bio-Techne Releases Second Quarter Fiscal 2025 Results
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million.GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago.Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy workflow solutions, led to 8% organic growth in our Protein Sciences Segment (7% reported).Strong commercial execution in Diagnostics & Spatial Biology led to 12% organic growth (12% report
2/5/25 6:30:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Bio-Techne Declares Dividend
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s
2/5/25 6:30:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 2:40 p.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website
2/4/25 8:00:00 AM ET
$RGLS
Biotechnology: Pharmaceutical Preparations
Health Care

$RGLS
$TECH
Leadership Updates

Live Leadership Updates

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors
MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th
2/4/25 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
4/30/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
1/5/24 7:00:00 AM ET
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Chat with this insight

Recent Analyst Ratings for $RGLS$TECH

$RGLS$TECH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Regulus Therapeutics with a new price target

Bio-Techne downgraded by Citigroup with a new price target

Leerink Partners initiated coverage on Regulus Therapeutics with a new price target

$RGLS$TECH Financials

Live finance-specific insights

Bio-Techne Releases Second Quarter Fiscal 2025 Results

Bio-Techne Declares Dividend

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

$RGLS$TECH Press Releases

Fastest customizable press release news feed in the world

Bio-Techne Releases Second Quarter Fiscal 2025 Results

Bio-Techne Declares Dividend

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

$RGLS$TECH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Hagan Joseph P bought $54,260 worth of shares (50,000 units at $1.09), increasing direct ownership by 24% to 260,808 units (SEC Form 4)

Director Baltimore David bought $20,787 worth of shares (19,610 units at $1.06), increasing direct ownership by 766% to 22,169 units (SEC Form 4)

Director Collier Kathryn J bought $7,280 worth of shares (4,000 units at $1.82), increasing direct ownership by 146% to 6,740 units (SEC Form 4)

$RGLS$TECH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

$RGLS$TECH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Herr Amy E. was granted 1,040 shares (SEC Form 4)

New insider Herr Amy E. claimed ownership of 1,860 shares (SEC Form 3)

President - DGS Mcmanus Matthew converted options into 4,620 shares and covered exercise/tax liability with 1,642 shares (SEC Form 4)

$RGLS$TECH Leadership Updates

Live Leadership Updates

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

$RGLS$TECH SEC Filings

SEC Form 10-Q filed by Bio-Techne Corp

Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

SEC Form S-8 filed by Regulus Therapeutics Inc.

Recent Analyst Ratings for
$RGLS
$TECH

$RGLS
$TECH
Analyst Ratings

$RGLS
$TECH
Financials

$RGLS
$TECH
Press Releases

$RGLS
$TECH
Insider Purchases

$RGLS
$TECH
Large Ownership Changes

$RGLS
$TECH
Insider Trading

$RGLS
$TECH
Leadership Updates

$RGLS
$TECH
SEC Filings